Compare · GILD vs SLXN
GILD vs SLXN
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Silexion Therapeutics Corp (SLXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and SLXN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $160.15B, about 78647.0x SLXN ($2.0M).
- Over the past year, GILD is up 18.3% and SLXN is down 96.6% - GILD leads by 114.9 points.
- GILD has been more active in the news (21 items in the past 4 weeks vs 17 for SLXN).
- GILD has more recent analyst coverage (25 ratings vs 0 for SLXN).
- Company
- Gilead Sciences Inc.
- Silexion Therapeutics Corp
- Price
- $129.01+1.15%
- $4.85-0.82%
- Market cap
- $160.15B
- $2.0M
- 1M return
- -2.80%
- -24.34%
- 1Y return
- +18.29%
- -96.60%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 21
- 17
- Recent ratings
- 25
- 0
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
- New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
- FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC
- FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC
- Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
Latest SLXN
- SEC Form PRE 14A filed by Silexion Therapeutics Corp
- Amendment: SEC Form SCHEDULE 13D/A filed by Silexion Therapeutics Corp
- Silexion Therapeutics Corp filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form S-8 filed by Silexion Therapeutics Corp
- Silexion Therapeutics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Silexion Therapeutics Announces 1-for-10 Reverse Share Split
- Amendment: SEC Form 10-K/A filed by Silexion Therapeutics Corp
- Silexion Therapeutics Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- SEC Form 10-Q filed by Silexion Therapeutics Corp